GNPX: Genprex, Inc. Stock

by  •  • Comments Off on GNPX: Genprex, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.73
Enterprise Value ($M) 3.26
Book Value ($M) 3.87
Book Value / Share 0.16
Price / Book 1.74
NCAV ($M) 2.02
NCAV / Share 0.08
Price / NCAV 3.33

Profitability (mra)
Return on Invested Capital (ROIC) -5.01
Return on Assets (ROA) -1.54
Return on Equity (ROE) -2.21

Liquidity (mrq)
Quick Ratio 1.94
Current Ratio 1.94

Balance Sheet (mrq) ($M)
Current Assets 4.16
Assets 6.01
Liabilities 2.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -21.17
Net Income -21.39
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -17.15
Cash from Investing 0.00
Cash from Financing 12.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-15 13G Forsakringsaktiebolaget Avanza Pension 0.02 -95.43
10-24 13G/A Otsuka Masaya 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2025-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-13 166,037 616,749 26.92
2025-05-12 380,391 1,044,514 36.42
2025-05-09 157,685 503,737 31.30
2025-05-08 225,383 702,538 32.08

(click for more detail)

Similar Companies
GLTO – Galecto, Inc. GLYC – GlycoMimetics, Inc.
GNLX – Genelux Corporation GOVX – GeoVax Labs, Inc.
GRCE – Grace Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io